NCT03225716 2024-05-03A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's MacroglobulinemiaDana-Farber Cancer InstitutePhase 1 Terminated13 enrolled 13 charts
NCT02666209 2017-08-28Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple MyelomaDana-Farber Cancer InstituteNo longer available